74. Prolactin secreting pituitary adenoma Disease details / Clinical trials / Drug dev / DR info
Clinical trials : 55 / Drugs : 76 - (DrugBank : 19) / Drug target genes : 17 - Drug target pathways : 83
Drugs, Primary sponsors and Trial info (Enrollment year, Phase, Trial ID, Countries)
Abilify
University of Oxford
2010 - EUCTR2009-011228-73-GB United Kingdom
Antipsychotic drugs inducing hyperprolactinemia
Fayoum University
2022 - NCT06040944 Egypt
Aripiprazole
Beijing HuiLongGuan Hospital
2013 - NCT02013232 China
Shandong Mental Health Center
2017 Phase 4 ChiCTR1900027504 China
Shanghai Mental Health Center
2013 - ChiCTR-IOC-15006485 China
2012 - ChiCTR-TRC-14004186 China
Si Tianmei
2013 Phase 4 NCT01742390 China
The Second Affiliated Hospital/ Xinxiang Medical University
2012 - ChiCTR-IOR-15006278 China
University of Maryland, Baltimore
2011 - NCT01338298 United States
University of Oxford
2010 Phase 4 NCT01085383 United Kingdom
2010 - EUCTR2009-011228-73-GB United Kingdom
Barley
Huashan Hospital Affiliated to Fudan University
2022 Phase 0 ChiCTR2200056078 China
Blood sampling
Shen Qu
2017 - NCT05528393 China
Blood test
University Hospital, Lille
2021 - NCT04746313 France
Bromocriptin
University Hospital, Bonn
2006 Phase 3 NCT00315081 Germany
Bromocriptin 2.5MG, 2-3 times A DAY
Second Affiliated Hospital, School of Medicine, Zhejiang University
2024 - NCT06556186 -
Bromocriptine
First affiliated hospital of Sun Yat-sen University
2012 - ChiCTR-ONC-12002194 -
Huashan Hospital Affiliated to Fudan University
2022 Phase 0 ChiCTR2200056078 China
Bromocriptine mesilate
North Lincolnshire and Goole NHS Foundation Trust
2010 Phase 4 EUCTR2010-021403-24-GB United Kingdom
Bromocriptine mesylate tablets
Changchun GeneScience Pharmaceutical Co., Ltd.
2025 Phase 3 NCT07124221 China
Cabergolin teva
Aarhus University Hospital, Department of Endocrinology
2022 Phase 2 EUCTR2021-005579-38-DK Denmark
Cabergoline
Aarhus University Hospital, Department of Endocrinology
2022 Phase 2 EUCTR2021-005579-38-DK Denmark
Federico II University
2007 - NCT00460616 Italy
Seoul National University Hospital
2018 - NCT03457389 Korea, Republic of
Universidade Federal do Rio de Janeiro
2010 Phase 2/Phase 3 NCT01620138 Brazil
University Hospital, Basel, Switzerland
2025 Phase 4 NCT07045935 Switzerland
University of Aarhus
2008 - NCT00699530 Denmark
University of Sao Paulo General Hospital
2026 Phase 3 NCT07463235 Brazil
Zealand University Hospital
2026 Phase 4 NCT07386080 Denmark
Cabergoline 1.5-2 MG/week).orally daily FOR 1 month plus health education
Woman's Health University Hospital, Egypt
2020 Phase 1 NCT04262024 Egypt
Cabergoline 1.5-2 MG/week).orally daily FOR 1 month without health education
Woman's Health University Hospital, Egypt
2020 Phase 1 NCT04262024 Egypt
Cabergoline tablets
Changchun GeneScience Pharmaceutical Co., Ltd.
2025 Phase 3 NCT07124221 China
Cabergoline tablets reference formulation
Changchun GeneScience Pharmaceutical Co., Ltd.
2025 Phase 1 NCT07008417 China
Cabergoline tablets test formulation
Changchun GeneScience Pharmaceutical Co., Ltd.
2025 Phase 1 NCT07008417 China
Calcium and vitamin D
University of Iowa
2008 - NCT00799383 United States
Clomiphene citrate
Federal University of São Paulo
2004 Phase 2 NCT00697814 Brazil
Control group: clomiphene citrate tablets
Xiyuan Hospital of China Academy of Chinese Medical Sciences
2019 Phase 2 NCT03709849 -
Curcumin
Mashhad University of Medical Sciences
2011 Phase 1 NCT01344291 Iran, Islamic Republic of
Dexamethasone
National Cancer Institute (NCI)
2010 Phase 1 NCT01088763 Canada;United States
Diagnostic laboratory biomarker analysis
National Cancer Institute (NCI)
2010 Phase 1 NCT01088763 Canada;United States
Dopamine
University Hospital, Basel, Switzerland
2025 Phase 4 NCT07045935 Switzerland
Zealand University Hospital
2026 Phase 4 NCT07386080 Denmark
Dopamine agonist treatment
First Affiliated Hospital, Sun Yat-Sen University
2016 - NCT03353025 China
Dopamine agonists
Leiden University Medical Center
2019 Phase 4 NCT04107480 Netherlands
Endoscopic trans-sphenoidal adenoma resection
Leiden University Medical Center
2019 Phase 4 NCT04107480 Netherlands
Experimental group: bushen culuan decoction
Xiyuan Hospital of China Academy of Chinese Medical Sciences
2019 Phase 2 NCT03709849 -
G02C B01
North Lincolnshire and Goole NHS Foundation Trust
2010 Phase 4 EUCTR2010-021403-24-GB United Kingdom
Gamma-secretase/notch signalling pathway inhibitor RO4929097
National Cancer Institute (NCI)
2010 Phase 1 NCT01088763 Canada;United States
Genotropin 12MG
Amar Agha, Beaumont Hospital
2009 Phase 4 EUCTR2009-010918-30-IE Ireland
Genotropin 5.3MG
Amar Agha, Beaumont Hospital
2009 Phase 4 EUCTR2009-010918-30-IE Ireland
Genotropin miniquick 0.2MG
Amar Agha, Beaumont Hospital
2009 Phase 4 EUCTR2009-010918-30-IE Ireland
Genotropin miniquick 0.4MG
Amar Agha, Beaumont Hospital
2009 Phase 4 EUCTR2009-010918-30-IE Ireland
Genotropin miniquick 0.6MG
Amar Agha, Beaumont Hospital
2009 Phase 4 EUCTR2009-010918-30-IE Ireland
Genotropin miniquick 0.8MG
Amar Agha, Beaumont Hospital
2009 Phase 4 EUCTR2009-010918-30-IE Ireland
Genotropin miniquick 1.0MG
Amar Agha, Beaumont Hospital
2009 Phase 4 EUCTR2009-010918-30-IE Ireland
Genotropin miniquick 1.2MG
Amar Agha, Beaumont Hospital
2009 Phase 4 EUCTR2009-010918-30-IE Ireland
Gnrh
Massachusetts General Hospital
2017 Phase 2 NCT02956447 United States
2009 Phase 1 NCT00914823 United States
HCQ/CQ and CAB combined treatment
Zhebao Wu
2018 - NCT03400865 China
Kisspeptin 112-121
Massachusetts General Hospital
2017 Phase 2 NCT02956447 United States
2009 Phase 1 NCT00914823 United States
Lapatinib
Cedars-Sinai Medical Center
2009 Phase 2 NCT00939523 United States
Licorice
Beijing Anding Hospital,Capital Medical University
2025 - ChiCTR2500111471 China
Luveris fixed dose
University Reproductive Associates
2009 Phase 4 NCT00889512 United States
Luveris increasing dose
University Reproductive Associates
2009 Phase 4 NCT00889512 United States
Metformin
Taipei Medical University Hospital
2010 - NCT06326840 Taiwan
Norprolac
North Lincolnshire and Goole NHS Foundation Trust
2010 Phase 4 EUCTR2010-021403-24-GB United Kingdom
Parlodel
North Lincolnshire and Goole NHS Foundation Trust
2010 Phase 4 EUCTR2010-021403-24-GB United Kingdom
Pasireotide
Memorial Sloan Kettering Cancer Center
2024 Phase 2 NCT06295952 United States
NOVARTIS FARMA
2009 - EUCTR2008-007348-32-IT France;Germany;Italy;Spain
Novartis Pharma Services AG
2009 Phase 2 EUCTR2008-007348-32-FR France;Germany;Italy;Spain
2009 Phase 2 EUCTR2008-007348-32-DE Argentina;Australia;Brazil;Canada;Colombia;France;Germany;Italy;Mexico;Russian Federation;South Africa;Spain;United States
Universidade Federal do Rio de Janeiro
2010 Phase 2/Phase 3 NCT01620138 Brazil
Universitätsklinikum Essen - Zentrum für Innere Medizin - Klinik für Endokrinologie
2008 - EUCTR2006-007036-95-DE Germany
PGD granules
The University of Hong Kong
2013 Phase 2 NCT01852331 China
Pharmacological study
National Cancer Institute (NCI)
2010 Phase 1 NCT01088763 Canada;United States
Pramipexole
Department of Neuropsychiatry,University of Fukui
2011 - JPRN-UMIN000006556 Japan
Quinagolide hydrochloride
North Lincolnshire and Goole NHS Foundation Trust
2010 Phase 4 EUCTR2010-021403-24-GB United Kingdom
Qunagolide
North Lincolnshire and Goole NHS Foundation Trust
2010 Phase 4 EUCTR2010-021403-24-GB United Kingdom
Risperidone
Shandong Mental Health Center
2017 Phase 4 ChiCTR1900027504 China
Shanghai Mental Health Center
2012 - ChiCTR-TRC-14004186 China
Risperidone or paliperidone
Si Tianmei
2013 Phase 4 NCT01742390 China
Ropinirole
Columbia University
2016 Phase 1/Phase 2 NCT03038308 United States
SF-36 and hads
Memorial Sloan Kettering Cancer Center
2024 Phase 2 NCT06295952 United States
SOM230
NOVARTIS FARMA
2009 - EUCTR2008-007348-32-IT France;Germany;Italy;Spain
Novartis Pharma Services AG
2009 Phase 2 EUCTR2008-007348-32-FR France;Germany;Italy;Spain
2009 Phase 2 EUCTR2008-007348-32-DE Argentina;Australia;Brazil;Canada;Colombia;France;Germany;Italy;Mexico;Russian Federation;South Africa;Spain;United States
Universitätsklinikum Essen - Zentrum für Innere Medizin - Klinik für Endokrinologie
2008 - EUCTR2006-007036-95-DE Germany
Somatropin
Amar Agha, Beaumont Hospital
2009 Phase 4 EUCTR2009-010918-30-IE Ireland
Study drug
Pfizer
2010 - NCT01270711 -
Surgery
Zhebao Wu
2018 - NCT03717454 -
Transnasal transsphenoidal pituitary lesion resection under neuroendoscopy
Second Affiliated Hospital, School of Medicine, Zhejiang University
2024 - NCT06556186 -
Transsphenoidal surgery treatment
First Affiliated Hospital, Sun Yat-Sen University
2016 - NCT03353025 China
University of Oxford
2010 - EUCTR2009-011228-73-GB United Kingdom
Antipsychotic drugs inducing hyperprolactinemia
Fayoum University
2022 - NCT06040944 Egypt
Aripiprazole
Beijing HuiLongGuan Hospital
2013 - NCT02013232 China
Shandong Mental Health Center
2017 Phase 4 ChiCTR1900027504 China
Shanghai Mental Health Center
2013 - ChiCTR-IOC-15006485 China
2012 - ChiCTR-TRC-14004186 China
Si Tianmei
2013 Phase 4 NCT01742390 China
The Second Affiliated Hospital/ Xinxiang Medical University
2012 - ChiCTR-IOR-15006278 China
University of Maryland, Baltimore
2011 - NCT01338298 United States
University of Oxford
2010 Phase 4 NCT01085383 United Kingdom
2010 - EUCTR2009-011228-73-GB United Kingdom
Barley
Huashan Hospital Affiliated to Fudan University
2022 Phase 0 ChiCTR2200056078 China
Blood sampling
Shen Qu
2017 - NCT05528393 China
Blood test
University Hospital, Lille
2021 - NCT04746313 France
Bromocriptin
University Hospital, Bonn
2006 Phase 3 NCT00315081 Germany
Bromocriptin 2.5MG, 2-3 times A DAY
Second Affiliated Hospital, School of Medicine, Zhejiang University
2024 - NCT06556186 -
Bromocriptine
First affiliated hospital of Sun Yat-sen University
2012 - ChiCTR-ONC-12002194 -
Huashan Hospital Affiliated to Fudan University
2022 Phase 0 ChiCTR2200056078 China
Bromocriptine mesilate
North Lincolnshire and Goole NHS Foundation Trust
2010 Phase 4 EUCTR2010-021403-24-GB United Kingdom
Bromocriptine mesylate tablets
Changchun GeneScience Pharmaceutical Co., Ltd.
2025 Phase 3 NCT07124221 China
Cabergolin teva
Aarhus University Hospital, Department of Endocrinology
2022 Phase 2 EUCTR2021-005579-38-DK Denmark
Cabergoline
Aarhus University Hospital, Department of Endocrinology
2022 Phase 2 EUCTR2021-005579-38-DK Denmark
Federico II University
2007 - NCT00460616 Italy
Seoul National University Hospital
2018 - NCT03457389 Korea, Republic of
Universidade Federal do Rio de Janeiro
2010 Phase 2/Phase 3 NCT01620138 Brazil
University Hospital, Basel, Switzerland
2025 Phase 4 NCT07045935 Switzerland
University of Aarhus
2008 - NCT00699530 Denmark
University of Sao Paulo General Hospital
2026 Phase 3 NCT07463235 Brazil
Zealand University Hospital
2026 Phase 4 NCT07386080 Denmark
Cabergoline 1.5-2 MG/week).orally daily FOR 1 month plus health education
Woman's Health University Hospital, Egypt
2020 Phase 1 NCT04262024 Egypt
Cabergoline 1.5-2 MG/week).orally daily FOR 1 month without health education
Woman's Health University Hospital, Egypt
2020 Phase 1 NCT04262024 Egypt
Cabergoline tablets
Changchun GeneScience Pharmaceutical Co., Ltd.
2025 Phase 3 NCT07124221 China
Cabergoline tablets reference formulation
Changchun GeneScience Pharmaceutical Co., Ltd.
2025 Phase 1 NCT07008417 China
Cabergoline tablets test formulation
Changchun GeneScience Pharmaceutical Co., Ltd.
2025 Phase 1 NCT07008417 China
Calcium and vitamin D
University of Iowa
2008 - NCT00799383 United States
Clomiphene citrate
Federal University of São Paulo
2004 Phase 2 NCT00697814 Brazil
Control group: clomiphene citrate tablets
Xiyuan Hospital of China Academy of Chinese Medical Sciences
2019 Phase 2 NCT03709849 -
Curcumin
Mashhad University of Medical Sciences
2011 Phase 1 NCT01344291 Iran, Islamic Republic of
Dexamethasone
National Cancer Institute (NCI)
2010 Phase 1 NCT01088763 Canada;United States
Diagnostic laboratory biomarker analysis
National Cancer Institute (NCI)
2010 Phase 1 NCT01088763 Canada;United States
Dopamine
University Hospital, Basel, Switzerland
2025 Phase 4 NCT07045935 Switzerland
Zealand University Hospital
2026 Phase 4 NCT07386080 Denmark
Dopamine agonist treatment
First Affiliated Hospital, Sun Yat-Sen University
2016 - NCT03353025 China
Dopamine agonists
Leiden University Medical Center
2019 Phase 4 NCT04107480 Netherlands
Endoscopic trans-sphenoidal adenoma resection
Leiden University Medical Center
2019 Phase 4 NCT04107480 Netherlands
Experimental group: bushen culuan decoction
Xiyuan Hospital of China Academy of Chinese Medical Sciences
2019 Phase 2 NCT03709849 -
G02C B01
North Lincolnshire and Goole NHS Foundation Trust
2010 Phase 4 EUCTR2010-021403-24-GB United Kingdom
Gamma-secretase/notch signalling pathway inhibitor RO4929097
National Cancer Institute (NCI)
2010 Phase 1 NCT01088763 Canada;United States
Genotropin 12MG
Amar Agha, Beaumont Hospital
2009 Phase 4 EUCTR2009-010918-30-IE Ireland
Genotropin 5.3MG
Amar Agha, Beaumont Hospital
2009 Phase 4 EUCTR2009-010918-30-IE Ireland
Genotropin miniquick 0.2MG
Amar Agha, Beaumont Hospital
2009 Phase 4 EUCTR2009-010918-30-IE Ireland
Genotropin miniquick 0.4MG
Amar Agha, Beaumont Hospital
2009 Phase 4 EUCTR2009-010918-30-IE Ireland
Genotropin miniquick 0.6MG
Amar Agha, Beaumont Hospital
2009 Phase 4 EUCTR2009-010918-30-IE Ireland
Genotropin miniquick 0.8MG
Amar Agha, Beaumont Hospital
2009 Phase 4 EUCTR2009-010918-30-IE Ireland
Genotropin miniquick 1.0MG
Amar Agha, Beaumont Hospital
2009 Phase 4 EUCTR2009-010918-30-IE Ireland
Genotropin miniquick 1.2MG
Amar Agha, Beaumont Hospital
2009 Phase 4 EUCTR2009-010918-30-IE Ireland
Gnrh
Massachusetts General Hospital
2017 Phase 2 NCT02956447 United States
2009 Phase 1 NCT00914823 United States
HCQ/CQ and CAB combined treatment
Zhebao Wu
2018 - NCT03400865 China
Kisspeptin 112-121
Massachusetts General Hospital
2017 Phase 2 NCT02956447 United States
2009 Phase 1 NCT00914823 United States
Lapatinib
Cedars-Sinai Medical Center
2009 Phase 2 NCT00939523 United States
Licorice
Beijing Anding Hospital,Capital Medical University
2025 - ChiCTR2500111471 China
Luveris fixed dose
University Reproductive Associates
2009 Phase 4 NCT00889512 United States
Luveris increasing dose
University Reproductive Associates
2009 Phase 4 NCT00889512 United States
Metformin
Taipei Medical University Hospital
2010 - NCT06326840 Taiwan
Norprolac
North Lincolnshire and Goole NHS Foundation Trust
2010 Phase 4 EUCTR2010-021403-24-GB United Kingdom
Parlodel
North Lincolnshire and Goole NHS Foundation Trust
2010 Phase 4 EUCTR2010-021403-24-GB United Kingdom
Pasireotide
Memorial Sloan Kettering Cancer Center
2024 Phase 2 NCT06295952 United States
NOVARTIS FARMA
2009 - EUCTR2008-007348-32-IT France;Germany;Italy;Spain
Novartis Pharma Services AG
2009 Phase 2 EUCTR2008-007348-32-FR France;Germany;Italy;Spain
2009 Phase 2 EUCTR2008-007348-32-DE Argentina;Australia;Brazil;Canada;Colombia;France;Germany;Italy;Mexico;Russian Federation;South Africa;Spain;United States
Universidade Federal do Rio de Janeiro
2010 Phase 2/Phase 3 NCT01620138 Brazil
Universitätsklinikum Essen - Zentrum für Innere Medizin - Klinik für Endokrinologie
2008 - EUCTR2006-007036-95-DE Germany
PGD granules
The University of Hong Kong
2013 Phase 2 NCT01852331 China
Pharmacological study
National Cancer Institute (NCI)
2010 Phase 1 NCT01088763 Canada;United States
Pramipexole
Department of Neuropsychiatry,University of Fukui
2011 - JPRN-UMIN000006556 Japan
Quinagolide hydrochloride
North Lincolnshire and Goole NHS Foundation Trust
2010 Phase 4 EUCTR2010-021403-24-GB United Kingdom
Qunagolide
North Lincolnshire and Goole NHS Foundation Trust
2010 Phase 4 EUCTR2010-021403-24-GB United Kingdom
Risperidone
Shandong Mental Health Center
2017 Phase 4 ChiCTR1900027504 China
Shanghai Mental Health Center
2012 - ChiCTR-TRC-14004186 China
Risperidone or paliperidone
Si Tianmei
2013 Phase 4 NCT01742390 China
Ropinirole
Columbia University
2016 Phase 1/Phase 2 NCT03038308 United States
SF-36 and hads
Memorial Sloan Kettering Cancer Center
2024 Phase 2 NCT06295952 United States
SOM230
NOVARTIS FARMA
2009 - EUCTR2008-007348-32-IT France;Germany;Italy;Spain
Novartis Pharma Services AG
2009 Phase 2 EUCTR2008-007348-32-FR France;Germany;Italy;Spain
2009 Phase 2 EUCTR2008-007348-32-DE Argentina;Australia;Brazil;Canada;Colombia;France;Germany;Italy;Mexico;Russian Federation;South Africa;Spain;United States
Universitätsklinikum Essen - Zentrum für Innere Medizin - Klinik für Endokrinologie
2008 - EUCTR2006-007036-95-DE Germany
Somatropin
Amar Agha, Beaumont Hospital
2009 Phase 4 EUCTR2009-010918-30-IE Ireland
Study drug
Pfizer
2010 - NCT01270711 -
Surgery
Zhebao Wu
2018 - NCT03717454 -
Transnasal transsphenoidal pituitary lesion resection under neuroendoscopy
Second Affiliated Hospital, School of Medicine, Zhejiang University
2024 - NCT06556186 -
Transsphenoidal surgery treatment
First Affiliated Hospital, Sun Yat-Sen University
2016 - NCT03353025 China